Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

342 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
GBA-associated PD: chances and obstacles for targeted treatment strategies.
Höglinger G, Schulte C, Jost WH, Storch A, Woitalla D, Krüger R, Falkenburger B, Brockmann K. Höglinger G, et al. J Neural Transm (Vienna). 2022 Sep;129(9):1219-1233. doi: 10.1007/s00702-022-02511-7. Epub 2022 May 31. J Neural Transm (Vienna). 2022. PMID: 35639160 Free PMC article. Review.
The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach.
Levin J, Maaß S, Schuberth M, Respondek G, Paul F, Mansmann U, Oertel WH, Lorenzl S, Krismer F, Seppi K, Poewe W, Wenning G; PROMESA study group; Giese A, Bötzel K, Höglinger G. Levin J, et al. Among authors: hoglinger g. J Neural Transm (Vienna). 2016 Apr;123(4):439-45. doi: 10.1007/s00702-016-1507-8. Epub 2016 Jan 25. J Neural Transm (Vienna). 2016. PMID: 26809243 Clinical Trial.
Differentiation of atypical Parkinson syndromes.
Höglinger GU, Kassubek J, Csoti I, Ehret R, Herbst H, Wellach I, Winkler J, Jost WH. Höglinger GU, et al. J Neural Transm (Vienna). 2017 Aug;124(8):997-1004. doi: 10.1007/s00702-017-1700-4. Epub 2017 Feb 27. J Neural Transm (Vienna). 2017. PMID: 28243754 Review.
The Progressive Supranuclear Palsy Clinical Deficits Scale.
Piot I, Schweyer K, Respondek G, Stamelou M; DescribePSP study group; ProPSP study group; MDS-endorsed PSP study group; Sckopke P, Schenk T, Goetz CG, Stebbins GT, Höglinger GU. Piot I, et al. Among authors: hoglinger gu. Mov Disord. 2020 Apr;35(4):650-661. doi: 10.1002/mds.27964. Epub 2020 Jan 17. Mov Disord. 2020. PMID: 31951049
Rare Variants in Specific Lysosomal Genes Are Associated With Parkinson's Disease.
Hopfner F, Mueller SH, Szymczak S, Junge O, Tittmann L, May S, Lohmann K, Grallert H, Lieb W, Strauch K, Müller-Nurasyid M, Berger K, Schormair B, Winkelmann J, Mollenhauer B, Trenkwalder C, Maetzler W, Berg D, Kasten M, Klein C, Höglinger GU, Gasser T, Deuschl G, Franke A, Krawczak M, Dempfle A, Kuhlenbäumer G. Hopfner F, et al. Among authors: hoglinger gu. Mov Disord. 2020 Jul;35(7):1245-1248. doi: 10.1002/mds.28037. Epub 2020 Apr 8. Mov Disord. 2020. PMID: 32267580
Drug safety profiles in geriatric patients with Parkinson's disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis.
Greten S, Müller-Funogea JI, Wegner F, Höglinger GU, Simon N, Junius-Walker U, Gerbel S, Krause O, Klietz M. Greten S, et al. Among authors: hoglinger gu. J Neural Transm (Vienna). 2021 Jan;128(1):49-60. doi: 10.1007/s00702-020-02276-x. Epub 2020 Dec 1. J Neural Transm (Vienna). 2021. PMID: 33263172 Free PMC article.
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. Front Neurol. 2021. PMID: 34659081 Free PMC article.
342 results